Gateway for Cancer Research accelerates practice-changing discoveries in cancer care by harnessing the unrelenting passion of the research community and empowering patients to triumph over their disease. All of this is guided by a clear vision: To shape a world in which a cancer diagnosis is no longer feared.
Explore Gateway’s cutting-edge research program
Learn more about Gateway and our critical mission
Donate today and help advance lifesaving cancer research
Our most prestigious giving level, Gateway Concierge is a dynamic ecosystem that allows forward-thinking philanthropists to co-create new possibilities in cancer care.
Gateway will connect global benefactors with world-class clinician-scientists to create a research program that will deliver results in the fight against cancer—enabling real human impact now.Get Started
Read about the unwavering patients and the researchers who are helping us put and end to cancer as we know it.
Patient Profile: Kent
Kent enrolled in a Gateway-funded trial to treat his acute myeloid leukemia. See what he and his doctor had to say about his experience in this trial.Watch Kent’s Story
9,000+ patients have been impacted by Gateway-funded trials to date.Read More
“Never again am I going to look at a birthday and say, ‘I can’t believe I’m going to be another year older.’ Now I’m saying, ‘I’m so glad to be another year older!’”
Why Give to Gateway
99 cents of every dollar donated to Gateway goes directly towards funding a clinical trial.Donate Now
2019 Young Investigator Award Recipient
Dr. Maria Rubinstein, medical oncology fellow at Memorial Sloan Kettering Cancer Center received the prestigious one-year grant totaling $50,000.Read About Dr. Rubinstein
Did You Know?
190+ clinical trials have been funded worldwide by Gateway since 1991.View Our Clinical Trials
Gateway only invests in Phase I and Phase II human clinical trials where true innovation and transformational discoveries happen.
Trial Type: Lung Cancer
Identification of Predictive Biomarkers to Prevent Pneumonitis in Patients with Non-Small Cell Lung Cancer Who are Receiving Immunotherapy (Phase II)
Ajay Sheshadri, MD
The University of Texas MD Anderson Cancer Center
Trial Type: Pancreatic Cancer
Novel Use of Pepinemab in Combination with Nivolumab and FOLFIRINOX Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma (Phase Ib/II)
David Linehan, MD
University of Rochester
Extraordinary Times Call for Extraordinary Measures
COVID-19 significantly disrupted patient access to clinical trials—research that can make a world of difference for those facing cancer. In response to this long-term trend, Gateway launched an innovative new funding program to support “decentralized” clinical studies that bring trials to the doorsteps of cancer patients by leveraging technology and at-home care.
Extraordinary Measures, an urgent new fundraising campaign unlike any we have ever conducted in our nearly 30-year history, will advance this new grant program, helping to ensure all those facing cancer continue to receive potentially lifesaving therapies.Read More
Fund One Day
It costs just $16.56 per patient per day in a Gateway-funded cancer clinical trial.
Help us fund another day of research, another week or more. You can even mark your gift with a special date, such as an anniverary, birthday, wedding, bar/bat mitzvah or graduation.